UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of prostate-specific antigen relapse in prostate cancer: A European consensus

International journal of clinical practice (Esher), 2004-04, Vol.58 (4), p.382-390

2004

Volltextzugriff (PDF)

PO-233 INTENSITY MODULATED HIGH-DOSE-RATE BRACHYTHERAPY AS MONOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER

Radiotherapy and oncology, 2012-05, Vol.103, p.S94-S94

2012

Volltextzugriff (PDF)

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy

Prostate cancer and prostatic diseases, 2012-09, Vol.15 (3), p.296-302

2012

Volltextzugriff (PDF)

Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe

Prostate cancer and prostatic diseases, 2009-03, Vol.12 (1), p.83-87

2009

Volltextzugriff (PDF)

P110 Efficacy and tolerability of 3- and 6-month depot formulations of leuprorelin acetate for advanced prostate cancer in daily clinical practice: Pooled data from 2 non-interventional studies

European urology supplements : official journal of the European Association of Urology, 2012-11, Vol.11 (5), p.228-229

2012

Volltextzugriff (PDF)

Advanced prostate cancer treatment guidelines: European perspective

BJU international, 2004-12, Vol.94 (s3), p.6-6

Tunn, U.W.

2004

Volltextzugriff (PDF)

Assessment and management of high‐risk patients

BJU international, 2004-12, Vol.94 (s3), p.11-13

Tunn, U.W.

2004

Volltextzugriff (PDF)

The significance of serum levels of insulin‐like growth factor‐1 in patients with prostate cancer

BJU international, 2000-01, Vol.85 (1), p.125-129

2000

Volltextzugriff (PDF)

Intermittent Androgen Blockade in Prostate Cancer: Rationale and Clinical Experience

European urology, 2000-10, Vol.38 (4), p.365-371

2000

Volltextzugriff (PDF)

Intermittent Endocrine Therapy of Prostate Cancer

European urology, 1996, Vol.30 (Suppl 1), p.22-25

Tunn, U.W.

1996

Volltextzugriff (PDF)

Management of prostate-specific antigen relapse in prostate cancer: A European consensus: Management of Psa Relapse in Prostate Cancer

International journal of clinical practice (Esher), 2004-04, Vol.58 (4), p.382-390

2004

Volltextzugriff (PDF)

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Urologia internationalis, 1998-01, Vol.60 (Suppl 1), p.9-17

1998

Volltextzugriff (PDF)

Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation

The Journal of urology, 1995-08, Vol.154 (2), p.399-401

1995

Volltextzugriff (PDF)

181 New 3D interstitial HDR brachytherapy technique combined with 3D external beam radiotherapy and androgen deprivation for localized prostate cancer: Preliminary results

Radiotherapy and oncology, 2000-05, Vol.55, p.93-93

2000

Volltextzugriff (PDF)

146 Dose-volume histograms (DVH) and a conformal index (COIN) to evaluate implant quality of a new hdr brachytherapy technique for prostate cancer: Results in 616 implants

Radiotherapy and oncology, 2000-05, Vol.55, p.78-78

2000

Volltextzugriff (PDF)

Response in patients with metastatic renal cell carcinoma (RCC) during the treatment with alpha interferon in combination with 5-fluoroucacil

European journal of cancer (1990), 1993, Vol.29, p.S234-S234

1993

Volltextzugriff (PDF)

Effects of estrogen deprivation on human benign prostatic hyperplasia

Journal of steroid biochemistry and molecular biology, 1993-03, Vol.44 (4), p.573-576

1993

Volltextzugriff (PDF)

Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors

Journal of steroid biochemistry and molecular biology, 1993-03, Vol.44 (4), p.557-563

1993

Volltextzugriff (PDF)

Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)

The Journal of urology, 1993-12, Vol.150 (6), p.1840-1844

1993

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Management of prostate-specific antigen relapse in prostate cancer: A European consensus

PO-233 INTENSITY MODULATED HIGH-DOSE-RATE BRACHYTHERAPY AS MONOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy

Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe

P110 Efficacy and tolerability of 3- and 6-month depot formulations of leuprorelin acetate for advanced prostate cancer in daily clinical practice: Pooled data from 2 non-interventional studies

Advanced prostate cancer treatment guidelines: European perspective

Assessment and management of high‐risk patients

The significance of serum levels of insulin‐like growth factor‐1 in patients with prostate cancer

Intermittent Androgen Blockade in Prostate Cancer: Rationale and Clinical Experience

Intermittent Endocrine Therapy of Prostate Cancer

Management of prostate-specific antigen relapse in prostate cancer: A European consensus: Management of Psa Relapse in Prostate Cancer

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation

181 New 3D interstitial HDR brachytherapy technique combined with 3D external beam radiotherapy and androgen deprivation for localized prostate cancer: Preliminary results

146 Dose-volume histograms (DVH) and a conformal index (COIN) to evaluate implant quality of a new hdr brachytherapy technique for prostate cancer: Results in 616 implants

Response in patients with metastatic renal cell carcinoma (RCC) during the treatment with alpha interferon in combination with 5-fluoroucacil

Effects of estrogen deprivation on human benign prostatic hyperplasia

Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors

Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)

Suchergebnisse filtern